Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients

Otology and Neurotology

Volumn 33, Issue 6, 2012, Pages 1046-1052

  Plotkin, Scott R ^a   Merker, Vanessa L ^a   Halpin, Chris ^b   Jennings, Dominique ^a   McKenna, Michael J ^b,c   Harris, Gordon J ^a   Barker II, Fred G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Bevacizumab; Neurofibromatosis; Schwannoma; VEGF; Vestibular

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; MALE; MIDDLE AGED; NEUROFIBROMATOSIS; NEUROMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUDIOMETRY, PURE-TONE; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84863950588     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e31825e73f5     Document Type: Review

References (34)

1. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet 2000;37:897-904.
2. Slattery WH III, Fisher LM, Iqbal Z, et al. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 2004;25:811-7.
3. Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 2004;25: 150-4.
4. Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 2010;31:1135-43.
5. Mulrow CD, Aguilar C, Endicott JE, et al. Quality-of-life changes and hearing impairment. A randomized trial. Ann Intern Med 1990; 113:188-94.
6. Kramer S. Hearing impairment, work, and vocational enablement. Int J Audiol Suppl 2008;2:S124-30.
7. Chia EM, Wang JJ, Rochtchina E, et al. Hearin impairment and health-related quality of life: The Blue Mountains Hearing Study. Ear Hear 2007;28:187-95.
8. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358-67.
9. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010;12:14-8.
10. Eminowicz GK, Raman R, Conibear J, et al. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: Report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 2012;126:79-82.
11. Mautner VF, Nguyen R, Knecht R, et al. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: Sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010;21:2294-5.
12. Mulvihill JJ, Parry DM, Sherman JL, et al. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990;113:39-52.
13. Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59: 1759-65.
14. Harris GJ, Plotkin SR, MacCollin M, et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008;62:1314-9.
15. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan- VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
16. Monsell EM. New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of OtolaryngologyYHead and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:176-8.
17. Hirsch IJ, Davis H, Silverman SR, et al. Development of materials for speech audiometry. J Speech Hear Disord 1952;17:321-37.
18. Thornton AR, Raffin MJ. Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res 1978;21:507-18.
19. Halpin C, Rauch SD. Using audiometric thresholds and word recognition in a treatment study. Otol Neurotol 2006;27:110-6.
20. Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of OtolaryngologyYHead and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:179-80.
21. Plotkin SR, Halpin C, Blakely JO, et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 2009;93:61-77.
22. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008. Computer Program.
23. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010;12:14-8.
24. Mautner VF, Nguyen R, Knecht R, et al. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: Sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010;21:2294-5.
25. Fisher LM, Doherty JK, Lev MH, et al. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: Neurofibromatosis 2 natural history consortium. Otol Neurotol 2009;30:835-41.
26. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27:4966-72.
27. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-93.
28. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.
29. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5.
30. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
31. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116: 2610-21.
32. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
33. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:83-8.
34. U.S. Food and Drug Administration. Changes in Bevacizumab Labeling. 10-4-2011. Ref Type: Online Source. Accessed October 4, 2011.